Cargando…

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors

SIMPLE SUMMARY: The capecitabine/temozolomide (CAPTEM) regimen has proven activity in pancreatic neuroendocrine tumors (NETs); however, data are limited in NETs of the small bowel. To observe whether this regimen has activity in this patient population, we conducted a retrospective study of all pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Toubah, Taymeyah, Morse, Brian, Strosberg, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870244/ https://www.ncbi.nlm.nih.gov/pubmed/35200546 http://dx.doi.org/10.3390/curroncol29020046

Ejemplares similares

Chemotherapy in Neuroendocrine Tumors
por: Das, Satya, et al.
Publicado: (2021)

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
por: Ünal, Çağlar, et al.
Publicado: (2023)

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016)

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
por: Barros, Milton J., et al.
Publicado: (2023)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis
por: Lu, Yaoheng, et al.
Publicado: (2018)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
por: Vijayvergia, Namrata, et al.
Publicado: (2020)

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
por: Douangprachanh, Sathathone, et al.
Publicado: (2022)

Cardiac Magnetic Resonance for Diagnosis of Neuroendocrine Tumor Metastases to the Right and Left Ventricles with Carcinoid Heart Disease
por: Barnebee, Daniel, et al.
Publicado: (2019)

Midgut neuroendocrine tumor presenting with acute intestinal ischemia
por: Mantzoros, Ioannis, et al.
Publicado: (2017)

Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours
por: Ohlsson, Håkan, et al.
Publicado: (2021)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Management of Small Bowel Neuroendocrine Tumors
por: Larouche, Vincent, et al.
Publicado: (2019)

MON-406 Two Cases of Aggressive Corticotroph Pituitary Tumors Treated with Capecitabine and Temozolomide
por: Tateno, Tae, et al.
Publicado: (2019)

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response
por: Owen, Dwight H., et al.
Publicado: (2017)

The Role of Endoscopy in Small Bowel Neuroendocrine Tumors
por: Yoon, Ji Yoon, et al.
Publicado: (2021)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review
por: Ishida, Atsushi, et al.
Publicado: (2022)

Small bowel volvulus with intussusception: an unusual revelation of neuroendocrine tumor
por: Lachhab, Imad, et al.
Publicado: (2015)

Small bowel gastrointestinal stromal tumor disguised as an adnexal mass: a source for midgut volvulus
por: Humenansky, Kayla M, et al.
Publicado: (2018)

A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report
por: Özdirik, Burcin, et al.
Publicado: (2021)

Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review
por: Zhang, Bin, et al.
Publicado: (2019)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation
por: Eng, Cathy, et al.
Publicado: (2021)

Small Bowel Neuroendocrine Tumors—10-Year Experience of the Ottawa Hospital (TOH)
por: Alfagih, Abdulhameed, et al.
Publicado: (2023)

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
por: Jeong, H., et al.
Publicado: (2021)

DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors
por: Cives, Mauro, et al.
Publicado: (2019)

PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma–paraganglioma origin
por: Remes, Satu Maria, et al.
Publicado: (2020)

Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors
por: Hiltunen, Niko, et al.
Publicado: (2022)

The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience
por: Das, Satya, et al.
Publicado: (2018)

Neuroendocrine Tumor Metastases to the Breast: A Case Report and Review of the Literature
por: Urrego Díaz, Jose A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iu2qqg08mpjh98gl00nvbekj66